My son has cancer. Kalshi wants you to be able to bet on his medical future
Joshua Pederson's son is part of a clinical trial for a novel cancer treatment. Kalshi, a prediction market, plans to allow betting on clinical trial results and regulatory decisions, which Pederson finds enraging.
Intelligence analysis by Llama
Kalshi's plan to allow betting on clinical trial results and regulatory decisions is met with opposition from Joshua Pederson, whose son is part of a clinical trial for a novel cancer treatment.
Imagine you're a kid with cancer, and there's a special treatment that might help you get better. But now, some people want to make money by betting on whether that treatment will work or not. It's like betting on a game, but the stakes are really high because it's your life. This is what's happening with Kalshi, a company that wants to let people bet on clinical trial results and regulatory decisions. It's a scary and unfair idea that could hurt people who are already going through a tough time.
Analysis
A $60B Vote of Confidence
Kalshi's plan to allow betting on clinical trial results and regulatory decisions has sparked controversy, with some arguing that it could hinder or harm potentially life-saving research. The company's CEO, Tarek Mansour, claims that the goal is to 'surface information' and provide a 'continuously updated, public probability that reflects the weight of the evidence.' However, critics argue that this is just another type of 'death market' that could put patients' lives at risk. The possibility of outside speculators betting against treatments for children, like Joshua Pederson's son, is particularly enraging. Kalshi is not currently allowing bets on treatments for children, but Mansour has been insistent in imagining a world where 'any difference in opinion' is a wagerable event. The Trump administration's efforts to keep the sector from being regulated have only added to the concerns. As Pederson notes, 'the idea that our family would turn to a prediction market to help us make these decisions – rather than to our extremely qualified team of oncologists – is preposterous.'
Why Cursor?
The question remains: why is Kalshi pushing forward with this plan? Mansour claims that the goal is to provide a more transparent and accurate way of predicting clinical trial outcomes. However, critics argue that this is just a thinly veiled attempt to make a profit off of patients' suffering. The fact that Kalshi is not currently allowing bets on treatments for children is a small consolation, but it does little to alleviate the concerns about the potential impact on patients. As Pederson notes, 'the possibility that somebody out there might be wagering against my son, hoping that the treatment fails so they can make money, is enraging.'
The Road Ahead
The future of Kalshi's plan is uncertain, but one thing is clear: the potential impact on patients and the integrity of clinical trials is a serious concern. As Pederson notes, 'the heavy majority of clinical trials do not succeed.' The possibility of outside speculators betting against treatments for children is a particularly enraging prospect. Kalshi's plan to allow betting on clinical trial results and regulatory decisions is a step in the wrong direction, and it's up to the company to reconsider its approach.
Key points
- Kalshi plans to allow betting on clinical trial results and regulatory decisions.
- The plan has sparked controversy, with some arguing that it could hinder or harm potentially life-saving research.
- Kalshi's CEO, Tarek Mansour, claims that the goal is to 'surface information' and provide a 'continuously updated, public probability that reflects the weight of the evidence.'
- Critics argue that this is just another type of 'death market' that could put patients' lives at risk.
- The possibility of outside speculators betting against treatments for children is particularly enraging.
If Kalshi's plan is implemented, it could lead to a more transparent and accurate way of predicting clinical trial outcomes. This could potentially lead to better decision-making for patients and their families.
The possibility of outside speculators betting against treatments for children is a particularly enraging prospect. This could lead to a decrease in the number of clinical trials and a decrease in the number of treatments available to patients.
